Asian Science Citation Index is committed to provide an authoritative, trusted and significant information by the coverage of the most important and influential journals to meet the needs of the global scientific community.  
ASCI Database
308-Lasani Town,
Sargodha Road,
Faisalabad, Pakistan
Fax: +92-41-8815544
Contact Via Web
Suggest a Journal
 
Articles by G. C. Shil
Total Records ( 1 ) for G. C. Shil
  P. K. Das , M. Mostofa , Q. Hasan , G. C. Shil and M. R. Islam
  The research work has conducted in 4 groups (each containing of 5 mice) of swiss albino mice following oral administration of H2-blockers and proton pump inhibitor (Ranitidine, Famotidine and Omeprazole) at the dose rate of 100 mgkg-1. b. wt. 13.33 mgkg-1. b. wt. and 3.33 mgkg-1 b. wt., respectively to investigate the toxic as well as gross pathological changes and also to estimate the blood glucose level. Loose faeces were found in group B (Ranitidine) during last few days of experimental period. Following post-mortem examination, congestion and pale colour of the liver was found in group C and D respectively. In the treatment group B (Ranitidine), TEC, TLC, Hb%, Monocyte, Neutrophil and Eosinophil count were significantly decreased whereas Lymphocyte was significantly increased in the same treatment group. The highest decrease in TEC (16.08%), TLC (17.77%), Hb% (20.75%), Monocyte (33.33%), Neutrophil (26.31%), Eosinophil (33.33%) was recorded. In the treatment group C (Famotidine), TLC, Monocyte count, blood level serum were significantly decrease whereas Lymphocyte count was significantly increased in the same treatment group. The highest decrease of TLC (17.41%), blood glucose (36.67%), Monocyte count (41.66%) was recorded. The highest increase of Lymphocyte was also recorded. In the treatment group D (Omeprazole), TLC, Monocyte count, blood glucose level were significantly decreased whereas Lymphocyte and neutrophil count was significantly increased. The highest decrease of TLC (23.28%) and Monocyte count was also recorded.
 
 
 
Copyright   |   Desclaimer   |    Privacy Policy   |   Browsers   |   Accessibility